Is platelet-activating factor produced during hemodialysis with AN-69 polyacrylonitrile membrane?

Nephron

Volumn 91, Issue 1, 2002, Pages 86-93

  Iatrou, Christos ^a,e   Afentakis, Nicolaos ^b   Nomikos, Tzortzis ^c   Dinas, Christos ^b   Stavropoulos Giokas, Catherine ^b   Antonopoulou, Smaragdi ^d  

^a IASO GENERAL HOSPITAL   (Greece)

^b KAT HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d HAROKOPIO UNIVERSITY   (Greece)

^e NONE   (Greece)

Author keywords

AN 69; Biocompatibility; Hemodialysis; Leukopenia; PAF; PAF acether; Polyacrylonitrile; Thrombocytopenia

Indexed keywords

ALCOHOL; COMPLEMENT COMPONENT C3A; COMPLEMENT MEMBRANE ATTACK COMPLEX; CUPROPHANE; POLYACRYLONITRILE; THROMBOCYTE ACTIVATING FACTOR;

ADULT; ARTICLE; AUTOANALYZER; BIOASSAY; BIOCOMPATIBILITY; CLINICAL ARTICLE; COLUMN CHROMATOGRAPHY; COMPARATIVE STUDY; CONTROLLED STUDY; DEVICE; EXTRACTION; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MEMBRANE; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PURIFICATION; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME;

ACRYLIC RESINS; ACRYLONITRILE; ADULT; AGED; CELLULOSE; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PLATELET ACTIVATING FACTOR; PLATELET COUNT; RENAL DIALYSIS;

EID: 0036094958     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057609     Document Type: Article

References (62)

1. Recent advantage in the biocompatibility of haemodialysis membranes
2. The hemodialysis membranes: A historical perspective, current state and future prospect
3. Chemistry and biology of acetyl glyceryl ether phosphorylcholine (platelet-activating factor)
4. Platelet-activating factor and the kidney
5. Potential role of platelet-activating factor in renal pathophysiology
6. The role of PAF-acether in anaphylaxis demonstrated with the use of the antagonist BN 52021
7. The role of platelet-activating factor in inflammation
8. PAF-acether (platelet-activating factor) and biocompatibility of hemodialysis membranes
9. The production of platelet-activating factor during he-modialysis
10. Increases in circulating level of platelet-activating factor lag behind transient neutropenia during hemodialysis with cuprophane membrane
11. The production of platelet-activating factor during hemodialysis with cuprophane membrane. Does the calcium concentration in the dialysate play any role on it?
12. Mechanisms and kinetics of the synthesis and release of platelet-activating factor by polyacrylonitrile membranes
13. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes
14. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis
15. Compartmental distribution of complement activation products in artificial kidneys
16. Human platelet activation by C3a and C3a des-arg
17. Mechanism involved in acute granulocytopenia in hemodialysis. Cell-membrane direct interactions
18. Mechanisms of neutropenia in hemodialysis
19. Direct interaction between polymorphonuclear neutrophils and cuprophane membrane in a plasma-free model of dialysis
20. Simple and precise method for the routine determination of platelet-activating factor in blood and urine
21. A rapid method of total lipid extraction and purification
22. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators)
23. Presence of PAF acether in blood during hemodialysis and its relation with dialysis leukopenia
24. Platelet-activating factor production during hemodialysis: Effect of BN52021
25. Anaphylatoxin formation during hemodialysis: Effects of different dialyzer membranes
26. Symptoms and activation of granulocytes and complement with two dialysis membranes
27. Anaphylatoxin formation during hemodialysis: Comparison of new and re-used dialyzers
28. The influence of the geometry of the dialyzer and the composition of the dialysate in activating the complement system
29. Generation of the membrane attack complex during haemodialysis: Impact of classical and alternative pathway components
30. Fluid phase generation of terminal complement complex as a novel index of biocompatibility
31. Assembly of terminal SC5b-9 complement complexes: A new index of blood-membrane interaction
32. C5b-9 generation and cytokine production in hemodialyzed patients
33. Synthetic modification of PAN membrane: Biocompatibility and functional characterization
34. Complement activation during extracorporeal therapy: Biochemistry, cell biology and clinical relevance
35. Transfusion of leukocytes and products of disintegrated leukocytes
36. Metabolic responses of neutrophils to uremia and dialysis
37. Plasma levels of main granulocyte components during hemodialysis. Comparison of new reused dialyser
38. Different complement and granulocyte activation dialysed with PMMA dialysers
39. Cationic proteins of human granulocytes: Effects on the complement system and mediation of chemotactic activity
40. Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils
41. Mediators of immune complex-induced aggregation of polymorphonuclear neutrophils. I. C5a anaphylotoxin neutrophil cationic proteins and their cleavage fragments
42. Reversal of hemodialysis granulocytopenia and pulmonary leukostasis
43. Hemodialysis-associated platelet activation and thrombocytopenia
44. Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design. Platelet activation and factor VIII-related von Willebrand factor during hemodialysis
45. Membrane effect on platelet function during hemodialysis: A comparison of cuprophane and polycarbonate
46. Biocompatibility of a new high-permeability modified cellulose membrane for haemodialysis
47. A method for measurement of platelet adhesiveness by use of dialysis membranes in a test-cell
48. A role of the platelet-dialysis membrane interaction in thrombus formation and blood loss during hemodialysis
49. Anti-thrombin-III and platelets in haemodialysis patients
50. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors
51. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer
52. Anaphylactoid reactions during hemodialysis and hemofiltration: Role of associating AN69 membrane and angiotensin I-converting enzyme inhibitors
53. Anaphylactoid reactions, angiotensin-converting enzyme inhibitors and extracorporeal hemotherapy
54. Accumulation of bradyki-nin formed by the ACE inhibitor in vitro
55. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes
56. Role of bradykinin in anaphylactoid reactions during hemodialysis with AN69 dialyzers
57. Bradykinin-mediated effect of ACE inhibition
58. Bioregulation of kinins: Kallikreins, kininogens, and kininases
59. Platelet-activating factor and related acetylated lipids as potent biological acting cellular mediators
60. Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate
61. Prevention of anaphylactoid reactions to high-flux membrane dialysis and ACE inhibitors by calcium
62. Kinin kinetics during different dialysis protocols with AN69 dialyser in ACEI-treated patients